Vaxart COVID-19 vaccine
Vaccine candidate against COVID-19
Pharmaceutical compound
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
 COVID-19 portal |
Vaxart COVID-19 vaccine is a COVID-19 vaccine candidate developed by Vaxart.[2][3][4] It is an enteric-coated tablet vaccine that can be administered orally.[5]
References
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ Clinical trial number NCT04563702 for "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults" at ClinicalTrials.gov
- ^ Clinical trial number NCT05067933 for "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)" at ClinicalTrials.gov
- ^ Clinical trial number NCT05067933 for "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine" at ClinicalTrials.gov
- ^ Braun MR, Flitter BA, Sun W, Tucker SN (October 2023). "An easy pill to swallow: oral recombinant vaccines for the 21st century". Current Opinion in Immunology. 84: 102374. doi:10.1016/j.coi.2023.102374. PMID 37562075.
Scholia has a profile for Vaxart COVID-19 vaccine (Q110269782).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
